Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
04 May, 2026, 06.00 AM IST
RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-SeptemberRPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...
30 Apr, 2026, 11.41 PM IST
Weight-loss drug craze for Ozempic, Mounjaro surges in India amid safety concernsIn India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic fo...
19 Apr, 2026, 06.11 AM IST
Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
17 Apr, 2026, 12.54 AM IST
Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
16 Apr, 2026, 07.31 AM IST
Boom or bust? Analysts reveal what lies ahead for India Inc in FY27 amid Iran warIndian businesses brace for 2026-27 with geopolitical tensions and AI reshaping industries. While core sectors show stability, policy shift...
02 Apr, 2026, 02.04 PM IST
Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
24 Mar, 2026, 11.14 AM IST
The promise of EU-India FTA for Indian patients: A case for price regulationThe EU-India FTA promises cheaper drugs and medical devices, but India's regulatory framework may hinder patient benefits. Current pricing ...
24 Feb, 2026, 10.29 AM IST
Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman & MD GV PrasadDr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimi...
23 Feb, 2026, 05.00 AM IST
Dr Reddy's shares jump 5% despite 14% YoY fall in Q3 profit. Should you buy, sell or hold?Dr Reddy's shares: The company posted a 14% year-on-year decline in consolidated net profit to Rs 1,210 crore.
22 Jan, 2026, 09.45 AM IST
Generic drug companies rework pricing to gain weight in India’s GLP-1 market as Novo Nordisk slashes Wegovy pricesIndian drugmakers are adjusting prices for weight-loss injections after Novo Nordisk cut prices for its drug Wegovy. This move is prompting...
27 Nov, 2025, 07.04 AM IST
Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow TuckerEli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...
19 Nov, 2025, 07.05 PM IST
Weight-loss drugs: Indian giants Dr Reddy’s to Macleods start preparing for Ozempic patent expiryIndian companies are gearing up to produce ingredients for generic weight-loss drugs. Novo Nordisk's patents are expiring soon. Dr Reddy's ...
17 Sep, 2025, 01.01 PM IST
Buy, Sell or Hold: Nuvama initiates coverage on Eureka Forbes; Religare Broking positive on RECBrokerages stay bullish: Nuvama starts Eureka Forbes with Buy (20% upside), Motilal Oswal reaffirms Biocon Buy (13% upside), Religare Broki...
17 Sep, 2025, 09.38 AM IST
Obesity lab: India becomes ground zero for weight-loss drug raceIndia is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expi...
22 Jul, 2025, 06.08 PM IST
Which pharma companies will benefit from latest government policies? Sumit Gupta explainsThe Indian pharmaceutical sector is poised for growth, driven by government support for R&D and manufacturing. Policies promoting bulk drug...
23 Dec, 2024, 08.11 AM IST